^
Association details:
| Biomarker: | KIF5B-RET fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Retevmo (selpercatinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
Published date:
05/18/2023
Excerpt:
A transbronchial tumor biopsy showed adenocarcinoma of the lung (Figure 3). DNA- and RNA-based next-generation sequencing of 648 tumor-associated genes (Tempus xT™ Version 4) identified a KIF5B-RET fusion and no other activating genomic aberrations….After the completion of neoadjuvant selpercatinib, the tumor decreased from 3.1 to 2.9 cm (Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 stable disease...
DOI:
https://doi.org/10.3389/fonc.2023.1178313
